Fairmount Funds Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $60.2M | Hold |
4,018,101
| – | – | 7.79% | 5 |
|
|
2025
Q1 | $64.8M | Hold |
4,018,101
| – | – | 10.06% | 3 |
|
|
2024
Q4 | $93.5M | Hold |
4,018,101
| – | – | 9.3% | 3 |
|
|
2024
Q3 | $118M | Hold |
4,018,101
| – | – | 9.58% | 4 |
|
|
2024
Q2 | $94.5M | Buy |
4,018,101
+3,639,680
| +962% | +$85.6M | 10.67% | 3 |
|
|
2024
Q1 | $14.4M | Hold |
378,421
| – | – | 1.56% | 14 |
|
|
2023
Q4 | $8.14M | Hold |
378,421
| – | – | 0.86% | 16 |
|
|
2023
Q3 | $4.64M | Sell |
378,421
-1
| -0% | -$12 | 0.56% | 20 |
|
|
2023
Q2 | $4.26M | Buy |
+378,422
| New | +$4.26M | 0.6% | 17 |
|